Immutep : 2021 Annual General Meeting and Key Dates

ASX/Media Release

2021 Annual General Meeting and Key Dates

SYDNEY, AUSTRALIA - 12 October 2021 - Immutep Limited(ASX: IMM; NASDAQ: IMMP) advises that it intends to hold its 2021 Annual General Meeting, (AGM) on Friday, 26 November 2021 commencing at 10.00am (AEDT).

The Company further advises that the closing time and date for receipt of director nominations for candidates other than those recommended by the Board is 5:00 pm, Tuesday, 19 October 2021.

Virtual AGM

Due to the ongoing impact of the COVID-19 pandemic and in consideration of the safety of shareholders, employees and the broader community, the Company will hold the AGM virtually rather than at a physical location this year.

Shareholders will be provided with more information on how to participate in the AGM in the Notice of the Meeting which will be released later this month on the Company's ASX market announcements page.

Notice of Meeting

In accordance with s253RA of the Corporations Act 2001 (inserted by the Treasury Laws Amendment (2021 Measures No. 1) Act 2021)), the Company will send the Notice of Meeting to shareholders electronically.

Shareholders who normally receive a hard copy of AGM related documents are encouraged to provide their email address to the share registry, Boardroom Limited at [e-mail] Thursday, 21 October 2021 to enable the Company to send the 2021 AGM related documentation by email.

Shareholders can also elect to receive future correspondence from the Company electronically by informing Boardroom Limited of this request via the above email address or by changing their communications election at https://www.investorserve.com.au/.

If you have not yet registered, you will need your shareholder information including SRN/HIN details.

This announcement was authorised for release by the Board of Immutep Limited.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep's current lead product candidate is eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep's large pharmaceutical partners.

Further information can be found on the Company's website www.immutep.comor by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

[phone]; [e-mail]

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 [phone]; [e-mail]

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889